SCHEMBL1103589

SCHEMBL1103589

Cc1ccc(-c2c3ccccc3c(-c3cccc4ccccc34)c3c2cnc2ccccc23)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP1A2 P05177 2/20 0.36
DHFR P00374 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
FLT3 P36888 1/20 0.35
GPR3 P46089 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 3/20 0.34
ATM Q13315 2/20 0.34
PDPK1 O15530 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103585 0.89 DHFR (0.40) ALDH1A1CYP1A2DHFRKDM4EGPR3
SCHEMBL1103468 0.87 KDM4E (0.44) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD
SCHEMBL1103247 0.86 KDM4E (0.46) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD
SCHEMBL1103525 0.85 MET (0.39) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD
SCHEMBL1103583 0.84 ALDH1A1 (0.42) SMN1; SMN2LMNAALDH1A1HPGDHTT
SCHEMBL1103412 0.84 ALDH1A1 (0.46) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD
SCHEMBL1103586 0.84 FLT3 (0.41) SMN1; SMN2LMNAALDH1A1HPGDHTT
SCHEMBL1103577 0.83 SSTR2 (0.39) SMN1; SMN2LMNAALDH1A1HPGDHTT
SCHEMBL1103610 0.82 KDM4E (0.40) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD
SCHEMBL1103569 0.82 KDM4E (0.42) SMN1; SMN2LMNAL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 SMN1; SMN2 4091/4885LMNA 2738/4885L3MBTL1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.